Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Trial Profile

Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMF 001 (Primary) ; MIS 416 (Primary)
  • Indications Prostate cancer; Urogenital cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 05 Jun 2018 Results (n=26) assessing safety, tolerabilty and immune response ( UMIN000008007 and UMIN000005246) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
  • 14 Mar 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top